Search results
Showing 841 to 855 of 1516 results for patients and public
In development Reference number: GID-TA11356 Expected publication date: TBC
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).
View recommendations for HTG139Show all sections
Sections for HTG139
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
In development Reference number: GID-TA11085 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
In development Reference number: GID-TA11862 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture [ID6276]
Awaiting development Reference number: GID-TA11363 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC